ZOLMITRIPTAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21N3O2
Molecular Weight	287.3574
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCc1c[nH]c2ccc(C[C@@]3([H])COC(=N3)O)cc12

InChI

InChIKey=ULSDMUVEXKOYBU-ZDUSSCGKSA-N

InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C16H21N3O2
Molecular Weight	287.3574
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9154322

Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura. The N-desmethyl metabolite also has high affinity for 5-HT1B/1D and moderate affinity for 5-HT1A receptors. Migraines are likely due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of Zomig for the treatment of migraine headache is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system, which result in cranial vessel constriction, and inhibition of pro-inflammatory neuropeptide release.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 1d (5-HT1d) receptor 46 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9154322	Agonist 2470
Serotonin 1b (5-HT1b) receptor 37 Target ID: CHEMBL1898 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9154322	Agonist 2470

Conditions

Condition	Modality	Targets	Highest Phase	Product
Migraine with aura 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf	Palliative		Approved 8043	ZOMIG Approved Use INDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Launch Date 8.80416E11
Migraine without aura 7 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf	Palliative		Approved 8043	ZOMIG Approved Use INDICATIONS & USAGE Zolmitriptan is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan are administered to treat any subsequent attacks. Zolmitriptan is not indicated for the prevention of migraine attacks. Safety and effectiveness of zolmitriptan have not been established for cluster headache. Zolmitriptan is a serotonin(5-HT)1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not indicated for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Launch Date 8.80416E11

C_max

Value	Dose	Analyte	Population
5.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
4.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
5.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
10.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
9.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
22.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

AUC

Value	Dose	Analyte	Population
16.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
23.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
30.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
32.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
32.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
54.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
55.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
71.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	0.925 mg single, intravenous dose: 0.925 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.5 mg single, oral dose: 2.5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.475 mg single, intravenous dose: 1.475 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.32 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	1.85 mg single, intravenous dose: 1.85 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
2.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9833595	2.95 mg single, intravenous dose: 2.95 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ZOLMITRIPTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
75% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020768s023,021231s014,021450s010lbl.pdf	unknown, unknown		ZOLMITRIPTAN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5 mg single, intranasal Highest studied dose Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	unhealthy, 41.7 ± 10.4 n = 783 Health Status: unhealthy Condition: Migraine Age Group: 41.7 ± 10.4 Sex: M+F Population Size: 783 Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	Disc. AE: Taste abnormality, Migraine aggravated... AEs leading to discontinuation/dose reduction: Taste abnormality (0.4%) Migraine aggravated (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845
50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13	Other AEs: Sedation... Other AEs: Sedation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13
5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	Disc. AE: Arrhythmia, Cerebral hemorrhage... AEs leading to discontinuation/dose reduction: Arrhythmia Cerebral hemorrhage Subarachnoid hemorrhage Stroke Gastrointestinal ischemia Peripheral vasoconstriction Serotonin syndrome Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Migraine aggravated	0.4% Disc. AE	5 mg single, intranasal Highest studied dose Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	unhealthy, 41.7 ± 10.4 n = 783 Health Status: unhealthy Condition: Migraine Age Group: 41.7 ± 10.4 Sex: M+F Population Size: 783 Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845
Taste abnormality	0.4% Disc. AE	5 mg single, intranasal Highest studied dose Dose: 5 mg Route: intranasal Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845	unhealthy, 41.7 ± 10.4 n = 783 Health Status: unhealthy Condition: Migraine Age Group: 41.7 ± 10.4 Sex: M+F Population Size: 783 Sources: https://pubmed.ncbi.nlm.nih.gov/12921494 Page: p.845
Sedation		50 mg single, oral Overdose Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.13
Arrhythmia	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Cerebral hemorrhage	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Gastrointestinal ischemia	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Peripheral vasoconstriction	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Serotonin syndrome	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Stroke	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1
Subarachnoid hemorrhage	Disc. AE	5 mg single, oral (max) Recommended Dose: 5 mg Route: oral Route: single Dose: 5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Migraine Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1601	substrate 936	substrate 1118 inhibitor 1702

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1383	CYP2C19 910 CYP1A2 972 P-gp 1400 OATP1A2 57

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2D6 1738	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0	weak
CYP1A2 1532	inhibitor 3045 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0	yes		yes (co-administration study) Comment: The increased exposure to zolmitriptan and 183C91 by cimetidine indicated that a reduction in the total daily recommended dose of zolmitriptan may be necessary when treating migraine patients who are taking nonspecific cytochrome P450 inhibitors or specific cytochrome 1A2 inhibitors. (https://pubmed.ncbi.nlm.nih.gov/18370509/) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=26 Page: 26.0

Drug as victim

Target	Modality	Activity	Metabolite
CYP1A2 972	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	no	N-desmethyl-zolmitriptan 1
CYP2C9 936	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	no	N-desmethyl-zolmitriptan 1
CYP2D6 1118	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	no	N-desmethyl-zolmitriptan 1
CYP2C19 910	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak
CYP2C19 910	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak	N-desmethyl-zolmitriptan 1
CYP2C9 936	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak
CYP3A4 1601	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/10553725/ Page: -	weak	N-desmethyl-zolmitriptan 1
CYP2D6 1118	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=25 Page: 25.0	yes
CYP3A4 1601	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020768ap_zomig_phrmrp1.pdf#page=25 Page: 25.0	yes
OATP1A2 57	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/22509823/ Page: -	yes
P-gp 1400	substrate 3113 Sources: https://pubmed.ncbi.nlm.nih.gov/17524230/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:10124	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10124
ChemicalBook	CB3313219	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3313219
MolPort	MolPort-003-666-626	https://www.molport.com/shop/molecule-link/MolPort-003-666-626
Selleck Chemicals	Zolmitriptan(Zomig)	http://www.selleckchem.com/products/Zolmitriptan(Zomig).html
ZINC	ZINC000000015515	http://zinc15.docking.org/substances/ZINC000000015515
eMolecules	2729142	https://www.emolecules.com/cgi-bin/more?vid=2729142

PubMed

Title	Date	PubMed
Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat.	1998 Jan	9489607
Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.	1998 Jun	9660035
[Mechanism of action of zolmitriptan].	1998 Oct	9859690
Global trends in migraine care: results from the MAZE survey.	2002	12196035
Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.	2002	11844897
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
The 1:1 inclusion compounds zolmitriptan-benzene and zolmitriptan-phenol.	2007 Jul	17609581
Prinzmetal-variant angina in a patient using zolmitriptan and citalopram.	2010 Feb	20159412

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dose of ZOMIG (zolmitriptan) is 1.25 mg or 2.5 mg. The 1.25 mg dose can be achieved by manually breaking the functionally-scored 2.5 mg tablet in half. The maximum recommended single dose of ZOMIG is 5 mg.

Route of Administration: Oral

In Vitro Use Guide

Stimulation of a Ca(2+)-dependent K(+) current by zolmitriptan was investigated in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Outward K(+) currents (I(K)) were examined in non-transfected C6 glioma cells and in cells expressing cloned human 5-HT(1B) receptors using the patch-clamp technique in the whole-cell configuration. In C6 glioma cells expressing recombinant human 5-HT 1B) receptor, zolmitriptan increased I(K) in a concentration-dependent manner (maximum increase 16.3+/-7.8%, n=5, p<0.001) with a pD(2) value (geometric mean with 95% confidence intervals) of 7.03 (7.90-6.10). Zolmitriptan failed to elicit increases in I(K) in non-transfected C6 cells.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:08:12 UTC 2021` Edited by `admin` on `Fri Jun 25 21:08:12 UTC 2021`
Record UNII	2FS66TH3YW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZOLMITRIPTAN

Official Name

English

311-C-90

Code

English

ZOLMITRIPTAN [WHO-DD]

Common Name

English

ZOLMITRIPTAN [USAN]

Common Name

English

ZOLMITRIPTAN [INN]

Common Name

English

ZOLMITRIPTAN [MART.]

Common Name

English

ZOLMITRIPTAN [EP MONOGRAPH]

Common Name

English

ZOLMITRIPTAN [MI]

Common Name

English

ZOLMITRIPTAN [ORANGE BOOK]

Common Name

English

311C90

Code

English

ZOLMITRIPTAN [VANDF]

Common Name

English

2-OXAZOLIDINONE, 4-((3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-5-YL)METHYL)-, (S)-

Systematic Name

English

ZOLMITRIPTAN [JAN]

Common Name

English

CVT-427

Common Name

English

(S)-4-((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)-2-OXAZOLIDINONE

Systematic Name

English

ZOLMITRIPTAN [USP MONOGRAPH]

Common Name

English

ZOLMITRIPTAN [USP-RS]

Common Name

English

NSC-760383

Code

English

ZOMIG

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QN02CC03

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

NCI_THESAURUS

C47794

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

NDF-RT

N0000175763

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

NDF-RT

N0000175765

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

WHO-ATC

N02CC03

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

LIVERTOX

1052

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

NDF-RT

N0000175764

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

Code System Code Type Description

FDA UNII

2FS66TH3YW

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

PUBCHEM

60857

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

CAS

139264-17-8

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

INN

7408

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

LACTMED

Zolmitriptan

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

IUPHAR

60

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

DRUG CENTRAL

2869

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

USP_CATALOG

1727009

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

USP-RS

WIKIPEDIA

ZOLMITRIPTAN

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

DRUG BANK

DB00315

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

NCI_THESAURUS

C47789

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

MESH

C089750

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

EPA CompTox

139264-17-8

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

RXCUI

135775

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

RxNorm

EVMPD

SUB00181MIG

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

MERCK INDEX

M11660

Created by admin on Fri Jun 25 21:08:13 UTC 2021 , Edited by admin on Fri Jun 25 21:08:13 UTC 2021

PRIMARY

Merck Index

ChEMBL

CHEMBL1185

Created by admin on Fri Jun 25 21:08:12 UTC 2021 , Edited by admin on Fri Jun 25 21:08:12 UTC 2021

PRIMARY

Related Record Type Details


					ZI18M2JAY5

5-HYDROXYTRYPTAMINE RECEPTOR 1D

TARGET -> AGONIST


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					UKK18ES9TF

5-HYDROXYTRYPTAMINE RECEPTOR 1A

TARGET -> AGONIST


					UE9PX4FTL0

5-HYDROXYTRYPTAMINE RECEPTOR 1B

TARGET -> AGONIST

Related Record Type Details


					22Y9Y8XC4U

ZOLMITRIPTAN N-OXIDE

METABOLITE INACTIVE -> PARENT


					UP93V5RS6K

N-DESMETHYL ZOLMITRIPTAN

METABOLITE ACTIVE -> PARENT


					XIJ30HC936

3-DES(DIMETHYLAMINOETHYL)-3-ACETIC ACID ZOLMITRIPTAN

METABOLITE INACTIVE -> PARENT

Related Record Type Details


					UP93V5RS6K

N-DESMETHYL ZOLMITRIPTAN

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					KUX4SO002X

2,2'-(4-(DIMETHYLAMINO)BUTANE-1,1-DIYL)BIS(5-((S)-(2-OXOOXAZOLIDIN-4-YL)METHYL)-3-(2-DIMETHYLAMINOETHYL)INDOLE)

IMPURITY -> PARENT


					F3YOE57701

ZOLMITRIPTAN, (R)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					22Y9Y8XC4U

ZOLMITRIPTAN N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					H8D1T877WE

DECARBONYL ZOLMITRIPTAN

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					22Y9Y8XC4U

ZOLMITRIPTAN N-OXIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					3FM32M4RD3

(4S)-4-((3-(2-AMINOETHYL)-1H-INDOL-5-YL)METHYL)-1,3-OXAZOLIDIN-2-ONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					DZ2G9845EY

(S)-3-(2-DIMETHYLAMINOETHYL)-5-(2-OXO-1,3-OXAZOLIDIN-4-YLMETHYL)-1H-INDOL-2-CARBOXYLIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					8FUG8LHT88

(4S)-4-((2-METHYL-1,2,3,4-TETRAHYDRO-9H-PYRIDO(3,4-B)INDOL-6-YL)METHYL)-1,3-OXAZOLIDIN-2-ONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					BJO4G2UWA4

(S)-4-(4-AMINOBENZYL)OXAZOLIDIN-2-ONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					H8D1T877WE

DECARBONYL ZOLMITRIPTAN

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					P64QEI4T0I

4,4-DIETHOXY-N,N-DIMETHYLBUTANAMINE

IMPURITY -> PARENT

Related Record Type Details


					2FS66TH3YW

ZOLMITRIPTAN

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC

Details

SMILES

InChI

DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdfCurator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9154322

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/9154322

C_max

T_1/2

F_unbound

Drug as perpetrator